BTIG analyst Marie Thibault reiterated a Buy rating on Insulet yesterday and set a price target of $380.00.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Marie Thibault’s rating is based on Insulet’s ambitious long-term growth targets and strategic initiatives. The company has set financial goals for 2026-2028, including a compound annual growth rate of approximately 20% in organic revenue, an annual expansion of adjusted operating margins by about 100 basis points, and a 25% compound annual growth rate in adjusted earnings per share. These targets are supported by Insulet’s plans to expand its manufacturing capabilities globally and increase its presence in the diabetes care market.
Additionally, Insulet’s pipeline of upcoming products and enhancements, such as the Omnipod 6 and integration with advanced sensors, positions the company to maintain its competitive edge. The company’s strategy to make automated insulin delivery systems a standard of care in the U.S. market, along with efforts to improve patient onboarding and customer acquisition, further support the positive outlook. Consequently, the Buy rating is reinforced by these growth prospects and strategic initiatives, leading to a revised price target of $380.
In another report released yesterday, Citi also assigned a Buy rating to the stock with a $380.00 price target.
Based on the recent corporate insider activity of 66 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of PODD in relation to earlier this year.